Hospital Acquired Disease Testing Market Size, Trends [2031]
Hospital Acquired Disease Testing Market Size, Trends [2031]
Segments - Hospital Acquired Disease Testing Market by Types (Methicilin-resistant Staphylococcus Aureus Testing, Urinary Tract Infection Testing, Bloodstream Infection Testing, Surgical Site Infection Testing, Pneumonia Testing, and Others) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-2534
| 4.6 Rating
| 73 Reviews
| 194 Pages
| Format :
Report Description
Hospital Acquired Disease Testing Market Outlook 2031
The Hospital Acquired Disease Testing Market was USD 3.94 Billion in 2022 and is likely to reach USD 7.62 Billion by 2031, expanding at a CAGR of 7.6% during 2023 – 2031. The growth of the market is attributed to rising prevalence of pathogens in hospitals. Moreover, increasing morbidity rates owing to various infections is driving the market growth.
Hospital acquired infections (HAIs), also known as nosocomial infections, usually occurs to people in the emergency rooms or intensive care units. The ripening period of these infections vary from 48 hours to four days after the patient getting admitted in medical facility. The prime reason of spread of HAIs are lack of proper hygiene and rising multi-drug resistant organisms. Some of nosocomial infections include primary bloodstream infections, pneumonia, and urinary tract infections (UTIs).
In some cases, the nosocomial infections are traced to the patients’ own microbiome. This happens when patient’s upper skin layer comes in contact with possible threats, especially after surgical operations. The frequently-used techniques that are being used for preventing HAIs are solid-phase hybridization, PCR, and, microarrays. Government bodies are providing guidelines for the control & prevention of hospital acquired diseases in developing countries.
Hospital Acquired Disease Testing Market Trends, Drivers, Restraints, and Opportunities
- The presence of efficient solutions for HAIs is expected to boost the market growth.
- The COVID-19 outbreak has increased the prevalence of HAIs, driving the growth of the market.
- Various government initiatives and healthcare authorities focusing on awareness about hospital acquired infection and available treatments are estimated to increase the demand for hospital acquired infection testing solutions.
- Increasing prevalence of HAIs is expected to proliferate the market growth.
- Rising investment by major market players for advancement in technology and innovative procedures are expected to create opportunities for the market growth.
Scope of Hospital Acquired Disease Testing Market Report
The report on the hospital acquired disease testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Hospital Acquired Disease Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Types (Methicilin-resistant Staphylococcus Aureus Testing, Urinary Tract Infection Testing, Bloodstream Infection Testing, Surgical Site Infection Testing, Pneumonia Testing, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Diatherix Laboratories Inc.; Life technologies; Qiagen GmbH; Nordion Inc.; Meridian Biosciences; Roche Diagnostics; Cepheid; Cantel Medical Corporation; and Others. |
Hospital Acquired Disease Market Segment Insights
Urinary tract infection testing segment is expected to grow at a rapid pace
Based on types, the market is segregated into methicilin-resistant staphylococcus aureus testing, urinary tract infection testing, bloodstream infection testing, surgical site infection testing, pneumonia testing, and others. The urinary tract infection testing segment is estimated to account for a key share of the market due to presence of advanced techniques to diagnose the hospital acquired diseases. On the other hand, the bloodstream infection testing segment is anticipated to expand at a rapid pace during the forecast period owing to rising number of government initiatives to control different types of HAIs.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to hold a large share of the market owing to various government regulations and growing healthcare infrastructure. On the other hand, the market of Asia Pacific is anticipated to expand at a healthy pace during the forecast period due to the growing medical tourism industry in countries such as India and China.
Segments
The global hospital acquired disease testing market has been segmented on the basis of
Types
- Methicilin-resistant Staphylococcus Aureus Testing
- Urinary Tract Infection Testing
- Bloodstream Infection Testing
- Surgical Site Infection Testing
- Pneumonia Testing
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Diatherix Laboratories Inc.
- Life technologies
- Qiagen GmbH
- Nordion Inc.
- Meridian Biosciences
- Roche Diagnostics
- Cepheid
- Cantel Medical Corporation
- Others
Competitive Landscape
Key players competing in the hospital acquired disease testing market are Diatherix Laboratories Inc.; Life technologies; Qiagen GmbH; Nordion Inc.; Meridian Biosciences; Roche Diagnostics; Cepheid; Cantel Medical Corporation; and others.
The main market players are continuously indulging in the activities such as mergers and acquisitions, research and developments, investments for innovative products and collaboration to expand their market share.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Hospital Acquired Disease Testing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hospital Acquired Disease Testing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hospital Acquired Disease Testing Market - Supply Chain
4.5. Global Hospital Acquired Disease Testing Market Forecast
4.5.1. Hospital Acquired Disease Testing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hospital Acquired Disease Testing Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Hospital Acquired Disease Testing Market Absolute $ Opportunity
5. Global Hospital Acquired Disease Testing Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Hospital Acquired Disease Testing Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Hospital Acquired Disease Testing Demand Share Forecast, 2019-2026
6. North America Hospital Acquired Disease Testing Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Hospital Acquired Disease Testing Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Hospital Acquired Disease Testing Demand Share Forecast, 2019-2026
7. Latin America Hospital Acquired Disease Testing Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Hospital Acquired Disease Testing Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Hospital Acquired Disease Testing Demand Share Forecast, 2019-2026
8. Europe Hospital Acquired Disease Testing Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Hospital Acquired Disease Testing Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Hospital Acquired Disease Testing Demand Share Forecast, 2019-2026
9. Asia Pacific Hospital Acquired Disease Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Hospital Acquired Disease Testing Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Hospital Acquired Disease Testing Demand Share Forecast, 2019-2026
10. Middle East & Africa Hospital Acquired Disease Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Hospital Acquired Disease Testing Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Hospital Acquired Disease Testing Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Hospital Acquired Disease Testing Market: Market Share Analysis
11.2. Hospital Acquired Disease Testing Distributors and Customers
11.3. Hospital Acquired Disease Testing Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Diatherix Laboratories Inc.
11.4.2. Life technologies
11.4.3. Qiagen GmbH
11.4.4. Nordion Inc.
11.4.5. Meridian Biosciences
11.4.6. Roche Diagnostics
11.4.7. Cepheid
11.4.8. Cantel Medical C
Methodology
Related Reports
Some other reports from this category!
Our Clients
